ARC, the innovation arm of Sheba Medical Center, has entered into a joint venture with Revealense to develop an artificial intelligence (AI) based platform for at-home neurological diagnostics.
The initiative aims to improve access, accuracy, and speed of diagnosis for conditions such as autism and attention-deficit hyperactivity disorder (ADHD). The first diagnostic protocols will address autism spectrum disorder, ADHD, and related conditions.
Led by Dr. Omer Bar Yosef, Director of the Child Development Center at Sheba Medical Center, the system is designed to enable assessments as early as six months of age. Unlike traditional methods, which often require lengthy clinical evaluations, the new approach allows patients to be assessed remotely through a standard webcam.
The platform integrates behavioral analysis with clinical expertise, offering the ability to establish baselines, track developmental changes over time, and generate tailored recommendations for treatment support. By conducting assessments in natural environments, it aims to reduce the variability and limitations often associated with clinic-based evaluations.
Revealense has developed a neurological AI engine that interprets behavioral and psychophysiological signals from video footage. Its patented platform, known as Illuminator, applies computational models and adaptive algorithms to produce real-time behavioral profiles. The joint venture plans to use this technology to provide clinically validated assessments for a broad range of neurological and cognitive conditions.
Strategic Goals And Market Timeline
According to Revealense CEO Dov Donin, the collaboration represents a significant step in advancing digital diagnostics. He stated that the partners expect to accelerate development and regulatory processes, with a market launch anticipated in early 2026.
Avner Halperin, CEO of Sheba Impact at ARC, highlighted the collaboration as an example of Sheba’s clinician-led innovation model. He noted that shifting diagnostics from the clinic to the home could improve both accessibility and efficiency while maintaining clinical reliability.
ARC (Accelerate, Redesign, Collaborate) is Sheba Medical Center’s innovation arm, supporting the development of clinician-led technologies and maintaining a global network of more than 300 hospitals across 12 countries. The collaboration with Revealense adds to its growing portfolio of AI-focused healthcare ventures.
Outlook
The joint venture between ARC and Revealense reflects an emerging trend in healthcare toward digital, personalized, and home-based diagnostic solutions. If successful, the initiative could establish a new standard for neurological assessments and expand the role of AI in clinical practice.
Multiple applications of artificial intelligence (AI) across drug and device development, diagnostics, and healthcare innovation. In the neuroscience field, Porosome Therapeutics is developing AI-designed peptides and organoid research, which is opening pathways toward new disease treatments for Alzheimer’s disease. Meanwhile, Linus Health is being acknowledged for advancing AI in Alzheimer’s detection, further reinforcing AI’s growing role in neurodegenerative disease diagnostics.
In diagnostic innovation, Sanome’s MEMORI platform gained UK CE certification for early infection detection, enabling the identification of infections up to 72 hours sooner, marking a leap in rapid diagnostic capability.
On the device and clinical operations front, Respiree secured $11.6 million to expand its AI-powered health monitoring solutions globally, highlighting investment trends toward scalable, remote patient monitoring.
